Genzyme Asks To Add New Patent To Arthritis Drug Suit

Law360, New York (April 26, 2011, 3:18 PM EDT) -- Genzyme Corp. sought Tuesday to add a newly issued patent to its ongoing infringement battle with Anika Therapeutics Inc. in Massachusetts federal court over Anika’s osteoarthritis drug Monovisc.

Genzyme asked the court for permission to supplement its July 2010 complaint to include an additional claim related to U.S. Patent Number 7,931,030 — which the U.S. Patent and Trademark Office just issued on Tuesday — arguing that adding the new patent to the case will not delay its progress.

“The use of the same product — Monovisc...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.